Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
Refardt J, Imber C, Sailer CO, Jeanloz N, Potasso L, Kutz A, Widmer A, Urwyler SA, Ebrahimi F, Vogt DR, Winzeler B, Christ-Crain M. Refardt J, et al. Among authors: vogt dr. J Am Soc Nephrol. 2020 Mar;31(3):615-624. doi: 10.1681/ASN.2019090944. Epub 2020 Feb 4. J Am Soc Nephrol. 2020. PMID: 32019783 Free PMC article. Clinical Trial.
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, Sartor O, Stenner-Liewen F. Meisel A, et al. Among authors: vogt dr. Eur J Cancer. 2016 Mar;56:93-100. doi: 10.1016/j.ejca.2015.12.009. Epub 2016 Jan 30. Eur J Cancer. 2016. PMID: 26829012 Clinical Trial.
Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Monnerat S, Bathelt C, Vogt DR, Berres M, Winzeler B, Bridenbaugh SA, Christ-Crain M. Refardt J, et al. Among authors: vogt dr. J Am Soc Nephrol. 2023 Feb 1;34(2):322-332. doi: 10.1681/ASN.2022050623. Epub 2022 Nov 17. J Am Soc Nephrol. 2023. PMID: 36396331 Free PMC article. Clinical Trial.
Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial.
Lengsfeld S, Burkard T, Meienberg A, Jeanloz N, Vukajlovic T, Bologna K, Steinmetz M, Bathelt C, Sailer CO, Vogt DR, Hemkens LG, Speich B, Urwyler SA, Kühne J, Baur F, Lutz LN, Erlanger TE, Christ-Crain M, Winzeler B. Lengsfeld S, et al. Among authors: vogt dr. EClinicalMedicine. 2023 Feb 21;57:101865. doi: 10.1016/j.eclinm.2023.101865. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36874396 Free PMC article.
Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.
Lüthi H, Lengsfeld S, Burkard T, Meienberg A, Jeanloz N, Vukajlovic T, Bologna K, Steinmetz M, Bathelt C, Sailer CO, Laager M, Vogt DR, Hemkens LG, Speich B, Urwyler SA, Kühne J, Baur F, Lutz LN, Erlanger TE, Christ-Crain M, Winzeler B. Lüthi H, et al. Among authors: vogt dr. EClinicalMedicine. 2024 Feb 9;68:102429. doi: 10.1016/j.eclinm.2024.102429. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38371479 Free PMC article.
50 results